The absence of a licensed vaccine for Sudan virus (SUDV) represents a meaningful gap in global outbreak preparedness — one that becomes especially urgent given that SUDV outbreaks, though less frequent than Ebola virus (EBOV) events, carry substantial fatality risk and have recently re-emerged in East Africa. A systematic comparison of the two pathogens' biology in humans could unlock a faster regulatory pathway by leveraging the vast body of EBOV evidence, and this review attempts exactly that.
Drawing on available human data spanning epidemiology, disease natural history, pathogenesis, and immune response, the analysis finds that EBOV and SUDV share remarkably parallel infection dynamics: similar routes of transmission, comparable clinical trajectories, and overlapping pathological signatures. Case fatality rates have generally been higher for EBOV disease than for SUDV disease, though the authors note this difference is heavily confounded by outbreak context — healthcare infrastructure, access to supportive care, and outbreak detection timing all materially influence survival outcomes. The structural and mechanistic similarities between the two viruses support a WHO prototype-pathogen framework, under which EBOV vaccine efficacy data could inform regulatory evaluation of SUDV candidates without requiring a completed field efficacy trial.
This analysis is scientifically significant because it directly addresses a long-standing regulatory and logistical impasse: SUDV outbreaks are sporadic enough that conducting a conventional Phase III efficacy trial in-country may be practically impossible. The prototype-pathogen concept, already applied to coronaviruses and influenza, could offer a viable precedent here. That said, key uncertainties remain. Cross-protection between filovirus-targeting vaccines is notably limited — licensed EBOV vaccines confer minimal protection against SUDV — meaning immunological bridging from EBOV data to SUDV will require rigorous validation of correlates of protection that may not fully translate. The review's reliance on observational outbreak data, with heterogeneous diagnostic and clinical reporting standards across decades, introduces substantial noise into any comparative conclusions. Still, as a framework paper, this represents a constructive and potentially accelerating contribution to filovirus vaccine development.